A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of COR388 in Older Healthy Volunteers and Patients With Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2018
At a glance
- Drugs COR-388 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Cortexyme
- 06 Mar 2018 Status changed from not yet recruiting to recruiting.
- 26 Jan 2018 Status changed from planning to not yet recruiting.
- 09 Jan 2018 New trial record